ClinicaliQ Trial Snapshot
- Pancreas Lipotoxicity in T2D: Edinburgh Diabetes Remission Study (EDRS) — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07364045.
- What is being tested: The study investigates pancreatic fat accumulation (lipotoxicity) as a mechanism in type 2 diabetes development and whether weight loss interventions can reverse pancreatic lipid deposition and restore beta cell function.
- Patient eligibility overview: The trial includes individuals with type 2 diabetes or those at high risk of developing the condition, with study design allowing assessment of pancreatic changes across different stages of glucose dysregulation and obesity status.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study aims to investigate how fat accumulation in the pancreas contributes to the development of type 2 diabetes (T2D), and how weight loss may reverse this process. Previous research has shown that reducing body weight can lead to diabetes remission, and this was accompanied by lowering intrapancreatic fat and restoration of insulin secretion, but the mechanisms behind this are not fully understood. In particular, the study aims to unravel the role of hepatic de novo lipogenesis (DNL) and lipoprotein metabolism on pancreas lipotoxicity and beta cell recovery after weight…
Eligibility Snapshot
- : * Overweight/obese (BMI: 30-45 kg/m²) who have had T2D for less than 6 years or longer than 10 years, and are on treatment with diet alone or diet plus oral medication. * Overweight/obese (BMI: 30-45 kg/m²) who are at pre-diabetes stage, defined as fasting blood glucose 5.6-6.9 mmol/L. * Overweight/obese (BMI: 30-45 kg/m²) who are non-diabetic (control group). * Age between 45 and 79 years inclusive. * Post-menopausal women only (to exclude sex hormone effects on lipid metabolism). * Good communication in English (able to give informed consent and follow dietary advice). * Willing and able to adhere to the study protocol, including dietary intervention and scheduled follow-up visits.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.